Search Legislation

Regulation (EC) No 999/2001 of the European Parliament and of the CouncilShow full title

Regulation (EC) No 999/2001 of the European Parliament and of the Council of 22 May 2001 laying down rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

Point in time view as at 18/03/2011.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EC) No 999/2001 of the European Parliament and of the Council, ANNEX X. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

ANNEX XU.K.REFERENCE LABORATORIES, SAMPLING AND LABORATORY ANALYSIS METHODS

CHAPTER AU.K.National reference laboratories

1.The designated national reference laboratory is to:U.K.

(a)

have at its disposal facilities and expert personnel enabling it to show at all times, and especially when the disease in question first appears, the type and strain of the agent of TSE, and to confirm results obtained by regional diagnostic laboratories. Where it is not capable of identifying the strain-type of the agent, it shall set up a procedure to ensure that the identification of the strain is referred to the Community reference laboratory;

(b)

verify diagnostic methods used in regional diagnostic laboratories;

(c)

be responsible for coordination of diagnostic standards and methods within the Member State. To this end, it:

  • may provide diagnostic reagents to laboratories approved by the Member State;

  • is to control the quality of all diagnostic reagents used in the Member State;

  • is to periodically arrange comparative tests;

  • is to hold isolates of the agents of the disease in question, or corresponding tissues containing such agents, coming from cases confirmed in the Member State;

  • is to ensure confirmation of results obtained in diagnostic laboratories designated by the Member State;

(d)

is to cooperate with the Community reference laboratory.

2.However, by way of derogation from point 1, Member States which do not have a national reference laboratory are to use the services of the Community reference laboratory or of national reference laboratories in other Member States.U.K.

[F13. The national reference laboratories are: U.K.

Austria:

Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH, Institut für veterinärmedizinische Untersuchungen Mödling

Robert Koch Gasse 17

A-2340 Mödling

Belgium:

CERVA -CODA-VAR

Centre d'Étude et de Recherches Vétérinaires et Agrochimiques

Centrum voor Onderzoek in Diergeneeskunde en Agrochemie

Veterinary and Agrochemical Research Centre

Groeselenberg 99

B-1180 Bruxelles

[F2Bulgaria:

Национален диагностичен научноизследователски ветеринарномедицински институт Проф. Д-р Георги Павлов

Национална референтна лаборатория Tрансмисивни спонгиформни енцефалопатии

бул. Пенчо Славейков

София 1606

(National Diagnostic Veterinary Research Institute Prof. Dr. Georgi Pavlov National Reference Laboratory for Transmissible Spongiform Encephalopathies

15, Pencho Slaveykov Blvd.

1606 Sofia)]

Cyprus:

State Veterinary Laboratories

Veterinary Services

CY-1417 Athalassa

Nicosia

Czech Republic:

Státní veterinární ústav Jihlava

Rantířovská 93

586 05 Jihlava

Denmark:

Danmarks Fødevareforskning

Bülowsvej 27

DK-1790 København V

Estonia:

Veterinaar- ja Toidulaboratoorium

Kreutzwaldi 30

Tartu 51006

Finland:

Eläinlääkintä- ja elintarvikelaitos

Hämeentie 57

FIN-00550 Helsinki

France:

Agence française de sécurité sanitaire des aliments

Laboratoire de pathologie bovine

31, avenue Tony Garnier

69 364 LYON CEDEX 07

Germany:

Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit

Anstaltsteil Insel Riems Boddenblick 5A

D-17498 Insel Riems

Greece:

Ministry of Agriculture — Veterinary Laboratory of Larisa

7th km of Larisa — Trikala Highway

GR-411 10 Larisa

Hungary:

Országos Állategészségügyi Intézet (OÁI)

Pf. 2.

Tábornok u. 2.

H-1581 Budapest

Ireland:

Central Veterinary Research Laboratory

Young's Cross

Celbridge

Co. Kildare

Italy:

Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d’Aosta — CEA

Via Bologna, 148

I-10154 Torino

Latvia:

State Veterinary Medicine Diagnostic Centre

Lejupes Str. 3

Riga LV 1076

Lithuania:

Nacionalinė veterinarijos laboratorija

J. Kairiūkščio g. 10

LT-08409 Vilnius

Luxembourg:

CERVA -CODA-VAR

Centre d'Étude et de Recherches Vétérinaires et Agrochimiques

Centrum voor Onderzoek in Diergeneeskunde en Agrochemie

Veterinary and Agrochemical Research Centre

Groeselenberg 99

B-1180 Bruxelles

Malta:

National Veterinary Laboratory

Albert Town Marsa

Netherlands:

Centraal Instituut voor Dierziektecontrole-Lelystad

Houtribweg 3g

8221 RA Lelystad

Postbus 2004

8203 AA Lelystad

Poland:

Państwowy Instytut Weterynaryjny (PIWet)

24-100 Puławy

al. Partyzantów 57

Portugal:

Laboratório Nacional de Investigação Veterinária Estrada de Benfica

701 P-1500 Lisboa

[F2Romania:

Institutul de Diagnostic și Sănătate Animală

Strada Dr. Staicovici nr. 63, sector 5

codul 050557, București.]

Slovakia:

State Veterinary Institute Zvolen

Pod dráhami 918

SK-960 86, Zvolen

Slovenia:

National Veterinary Institute

Gerbičeva 60

1000 Ljubljana

Spain:

Laboratorio Central de Veterinaria (Algete)

Ctra. de Algete km. 8

28110 Algete (Madrid)

Sweden:

National Veterinary Institute

S-751 89 Uppsala

United Kingdom:

Veterinary Laboratories Agency

Woodham Lane

New Haw Addlestone Surrey KT15 3NB]

CHAPTER BU.K.Community reference laboratory

1.The Community reference laboratory for TSEs is:U.K.

The Veterinary Laboratories Agency

Woodham Lane

New Haw

Addlestone

Surrey KT15 3NB

United Kingdom

2.The functions and duties of the Community reference laboratory are:U.K.

(a)

to coordinate, in consultation with the Commission, the methods employed in the Member States for diagnosing BSE, specifically by:

  • storing and supplying corresponding tissues containing the agent, for the development or production of the relevant diagnostic tests or for typing strains of the agent;

  • supplying standard sera and other reference reagents to the national reference laboratories in order to standardise the tests and reagents used in the Member States;

  • building up and retaining a collection of corresponding tissues containing the agents and strains of TSEs;

  • organising periodic comparative tests of diagnostic procedures at Community level;

  • collecting and collating data and information on the methods of diagnosis used and the results of tests carried out in the Community;

  • characterising isolates of the TSE agent by the most up-to-date methods to allow greater understanding of the epidemiology of the disease;

  • keeping abreast of trends in surveillance, epidemiology and prevention of TSEs throughout the world;

  • maintaining expertise on prion diseases to enable rapid differential diagnosis;

  • acquiring a thorough knowledge of the preparation and use of diagnostic methods used to control and eradicate TSEs;

(b)

to assist actively in the diagnosis of outbreaks of TSEs in Member States by studying samples from TSE-infected animals sent for confirmatory diagnosis, characterisation and epidemiological studies;

(c)

to facilitate the training or retraining of experts in laboratory diagnosis with a view to the harmonisation of diagnostic techniques throughout the Community.

[F3CHAPTER C U.K. Sampling and laboratory testing

[F41. Sampling U.K.

Any samples intended to be examined for the presence of a TSE shall be collected using the methods and protocols laid down in the latest edition of the Manual for diagnostic tests and vaccines for Terrestrial Animals of the International Office for Epizooties (IOE/OIE) (the Manual). In addition, or in the absence, of OIE methods and protocols, and to ensure that sufficient material is available, the competent authority shall ensure the use of sampling methods and protocols in accordance with guidelines issued by the Community Reference Laboratory. In particular the competent authority shall collect the appropriate tissues, according to the available scientific advice and the guidelines of the Community Reference Laboratory, in order to ensure the detection of all known strains of TSE in small ruminants and shall keep at least half of the collected tissues fresh but not frozen until the result of the rapid test is negative. Where the result is positive or inconclusive the residual tissues must be processed in accordance with the Community reference laboratory guidelines.

The samples shall be correctly marked as to the identity of the sampled animal.]

2. Laboratories U.K.

Any laboratory examination for TSE shall be carried out in laboratories approved for that purpose by the competent authority.

3. Methods and protocols U.K.

3.1. Laboratory testing for the presence of BSE in bovine animals U.K.
[F5(a) Suspect cases U.K.

Samples from bovine animals sent for laboratory testing pursuant to the provisions of Article 12(2) shall immediately be subjected to confirmatory examinations using at least one of the following methods and protocols laid down in the latest edition of the Manual:

(i)

the immunohistochemical (IHC) method;

(ii)

SAF-immunoblot or OIE approved alternative;

(iii)

the demonstration of characteristic fibrils by electron microscopy;

(iv)

the histopathological examination;

(v)

the combination of rapid tests as laid down in the third subparagraph.

In case the histopathological examination is inconclusive or negative, the tissues shall be submitted to a further examination by one of the other confirmatory methods and protocols.

Rapid tests may be used for both primary screening of suspect cases and, if inconclusive or positive, for subsequent confirmation, according to the guidelines from the Community reference laboratory and provided that:

(i)

the confirmation is carried out in a national reference laboratory for TSEs; and

(ii)

one of the two rapid tests is a Western blot; and

(iii)

the second rapid test used:

  • includes a negative tissue control and a bovine BSE sample as positive tissue control,

  • is of a different type than the test used for the primary screening; and

(iv)

if a rapid Western blot is used as the first test, the result of that test must be documented and submitted to the national reference laboratory for TSEs; and

(v)

where the result of the primary screening is not confirmed by the subsequent rapid test, the sample must be subjected to an examination by one of the other confirmatory methods; in case the histopathological examination is used for that purpose but proves to be inconclusive or negative, the tissues must be submitted to a further examination by one of the other confirmatory methods and protocols.

If the result of one of the confirmatory examinations referred to in points (i) to (v) of the first subparagraph is positive, the animals shall be regarded a positive BSE cases.

(b) BSE monitoring U.K.

Samples from bovine animals sent for laboratory testing pursuant to the provisions of Annex III, Chapter A, Part I shall be examined by a rapid test.

When the result of the rapid test is inconclusive or positive, the sample shall immediately be subjected to confirmatory examinations using at least one of the following methods and protocols laid down in the latest edition of the Manual:

(i)

the immunohistochemical (IHC) method;

(ii)

SAF-immunoblot or OIE approved alternative;

(iii)

the demonstration of characteristic fibrils by electron microscopy;

(iv)

the histopathological examination;

(v)

the combination of rapid tests as laid down in the fourth subparagraph.

In case the histopathological examination is inconclusive or negative, the tissues shall be submitted to a further examination by one of the other confirmatory methods and protocols.

Rapid tests may be used for both primary screening and, if inconclusive or positive, for subsequent confirmation, according to the guidelines from the Community reference laboratory and provided that:

(i)

the confirmation is carried out in a national reference laboratory for TSEs; and

(ii)

one of the two rapid tests is a Western blot; and

(iii)

the second rapid test used:

  • includes a negative tissue control and a bovine BSE sample as positive tissue control,

  • is of a different type than the test used for the primary screening; and

(iv)

if a rapid Western blot is used as the first test, the result of that test must be documented and submitted to the national reference laboratory for TSEs; and

(v)

where the result of the primary screening is not confirmed by the subsequent rapid test, the sample must be subjected to an examination by one of the other confirmatory methods; in case the histopathological examination is used for that purpose but proves to be inconclusive or negative, the tissues must be submitted to a further examination by one of the other confirmatory methods and protocols.

An animal shall be regarded a positive BSE case if the result of the rapid test is inconclusive or positive, and at least one of the confirmatory examinations referred to in points (i) to (v) of the first subparagraph is positive.]

3.2. Laboratory testing for the presence of TSE in ovine and caprine animals U.K.
[F5(a) Suspect cases U.K.

Samples from ovine and caprine animals sent for laboratory testing pursuant to the provisions of Article 12(2) shall immediately be subjected to confirmatory examinations using at least one of the following methods and protocols laid down in the latest edition of the Manual:

(i)

the immunohistochemical (IHC) method;

(ii)

SAF-immunoblot or OIE approved alternative;

(iii)

the demonstration of characteristic fibrils by electron microscopy;

(iv)

the histopathological examination.

In case the histopathological examination is inconclusive or negative, the tissues shall be submitted to a further examination by one of the other confirmatory methods and protocols.

Rapid tests may be used for primary screening of suspect cases. Such tests may not be used for subsequent confirmation.

Where the result of the rapid test used for primary screening of suspect cases is positive or inconclusive, the sample shall be subjected to an examination by one of the confirmatory examinations referred to in points (i) to (iv) of the first subparagraph. In case the histopathological examination is used for that purpose but proves to be inconclusive or negative, the tissues shall be submitted to a further examination by one of the other confirmatory methods and protocols.

If the result of one of the confirmatory examinations referred to in point (i) to (iv) of the first subparagraph is positive, the animals shall be regarded positive TSE cases and further examination as referred to in point (c) shall be performed.]

[F4(b) TSE monitoring U.K.

Samples from ovine and caprine animals sent for laboratory testing pursuant to the provisions of Annex III, Chapter A, Part II (Monitoring in ovine and caprine animals) shall be examined by a rapid test using the appropriate methods and protocols, according to the available scientific advice and the guidelines of the Community Reference Laboratory, in order to ensure the detection of all known strains of TSE.

When the result of the rapid test is inconclusive or positive, the sampled tissues shall immediately be sent to an official laboratory for confirmatory examinations by immunocytochemistry, immuno-blotting or demonstration of characteristic fibrils by electron microscopy, as referred to in (a). If the result of the confirmatory examination is negative or inconclusive, additional confirmatory testing shall be carried out according the guidelines of the Community reference laboratory.

If the result of one of the confirmatory examination is positive, the animal shall be regarded a positive TSE case.]

[F5(c) Further examination of positive TSE cases] U.K.
(i)

[F5Primary molecular testing with a discriminatory immuno-blotting

Samples from clinical suspect cases and from animals tested in accordance with Annex III, Chapter A, Part II, points 2 and 3 which are regarded as positive TSE cases but which are not atypical scrapie cases, following the examinations referred to in points (a) or (b), or which display characteristics which are deemed by the testing laboratory to merit investigation, shall be forwarded for further examination by a primary molecular typing method to:

  • Agence Française de Sécurité Sanitaire des Aliments, Laboratoire de pathologie bovine, 31 avenue Tony Garnier, BP 7033, F-69342, Lyon Cedex, France ,

  • Veterinary Laboratories Agency, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, United Kingdom , or

  • to a laboratory, appointed by the competent authority, which has participated successfully in proficiency testing organised by the Community reference laboratory for the use of a molecular typing method.]

(ii)

Ring trial with additional molecular testing methods

Samples from [F5TSE] cases in which the presence of BSE cannot be excluded according to the guidelines issued by the Community Reference Laboratory by the primary molecular testing referred to in (i), shall be forwarded immediately to the laboratories listed in point (d) after consultation with the Community Reference Laboratory, and with all the relevant information available. They shall be submitted to a ring trial with at least:

  • a second discriminatory immuno-blotting,

  • a discriminatory immunocytochemistry, and

  • a discriminatory ELISA (Enzyme linked ImmunoSorbent Assay)

carried out in the laboratories approved for the relevant method as listed in point (d). Where samples are unsuitable for immunocytochemistry, the Community Reference Laboratory will direct appropriate alternative testing within the ring trial.

The results shall be interpreted by the Community Reference Laboratory assisted by a panel of experts including a representative of the relevant National Reference Laboratory. The Commission shall be informed immediately about the outcome of that interpretation. Samples indicative for BSE by three different methods and samples inconclusive in the ring trial shall be further analysed by a mouse bioassay for final confirmation.

[F4Further testing of positive TSE samples detected in infected flocks on the same holding shall be carried out at least on the first two positive TSE cases detected every year following the index case.]

(d) Laboratories approved for performing further examination by molecular typing methods U.K.

The laboratories approved for further molecular typing are:

  • Agence Française de Sécurité Sanitaire des Aliments

    Laboratoire de pathologie bovine

    31, avenue Tony Garnier

    BP 7033

    F-69342 Lyon Cedex

  • Centre CEA Fontenay-aux-Roses, BP 6

    F-92265 Fontenay-aux-Roses Cedex

  • Service de Pharmacologie et d’Immunologie

    Centre CEA Saclay, bâtiment 136

    F-91191 Gif-sur-Yvette Cedex

  • Veterinary Laboratories Agency

    Woodham Lane

    New Haw

    Addlestone

    Surrey KT15 3NB

    United Kingdom

3.3. Laboratory testing for the presence of TSEs in species other than those referred to in points 3.1. and 3.2. U.K.

Where methods and protocols are established for tests carried out to confirm the suspected presence of a TSE in a species other than bovine, ovine and caprine, they shall include at least a histopathological examination of brain tissue. The competent authority may also require laboratory tests such as immunocytochemistry, immuno-blotting, demonstration of characteristic fibrils by electron microscopy or other methods designed to detect the disease associated form of the prion protein. In any case at least one other laboratory examination shall be carried out if the initial histopathological examination is negative or inconclusive. At least three different examinations shall be carried out in the event of the first appearance of the disease.

In particular, where BSE is suspected in a species other than bovine animals, samples shall be submitted for strain-typing, where possible.

[F64. Rapid tests U.K.

For the purposes of carrying out the rapid tests in accordance with Articles 5(3) and 6(1), only the following methods shall be used as rapid tests for the monitoring of BSE in bovine animals:

  • the immuno-blotting test based on a Western blotting procedure for the detection of the Proteinase K-resistant fragment PrPRes (Prionics-Check Western test),

  • the chemiluminescent ELISA test involving an extraction procedure and an ELISA technique, using an enhanced chemiluminescent reagent (Enfer test & Enfer TSE Kit version 2.0, automated sample preparation),

  • the microplate-based immunoassay for the detection of PrPSc (Enfer TSE Version 3),

  • the sandwich immunoassay for PrPRes detection (short assay protocol) carried out following denaturation and concentration steps (Bio-Rad TeSeE SAP rapid test),

  • the microplate-based immunoassay (ELISA) which detects Proteinase K-resistant PrPRes with monoclonal antibodies (Prionics-Check LIA test),

  • the immunoassay using a chemical polymer for selective PrP Sc capture and a monoclonal detection antibody directed against conserved regions of the PrP molecule (IDEXX HerdChek BSE Antigen Test Kit, EIA & IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA),

  • the lateral-flow immunoassay using two different monoclonal antibodies to detect Proteinase K-resistant PrP fractions (Prionics Check PrioSTRIP),

  • the two-sided immunoassay using two different monoclonal antibodies directed against two epitopes presented in a highly unfolded state of bovine PrP Sc (Roboscreen Beta Prion BSE EIA Test Kit),

  • the sandwich ELISA for the detection of Proteinase K-resistant PrP Sc (Roche Applied Science PrionScreen).

For the purposes of carrying out the rapid tests in accordance with Articles 5(3) and 6(1), only the following methods shall be used as rapid tests for the monitoring of TSE in ovine and caprine animals:

  • the sandwich immunoassay for PrPRes detection (short assay protocol) carried out following denaturation and concentration steps (Bio-Rad TeSeE SAP rapid test),

  • the sandwich immunoassay for PrPRes detection with the TeSeE Sheep/Goat Detection kit carried out following denaturation and concentration steps with the TeSeE Sheep/Goat Purification kit (Bio-Rad TeSeE Sheep/Goat rapid test),

  • the immunoassay using a chemical polymer for selective PrP Sc capture and a monoclonal detection antibody directed against conserved regions of the PrP molecule (IDEXX HerdChek BSE-Scrapie Antigen Test Kit, EIA).

In all rapid tests, sample tissue on which the test must be applied must comply with the manufacturer’s instructions for use.

Producers of rapid tests must have a quality assurance system in place that has been approved by the European Union Reference Laboratory and ensures that the test performance does not change. Producers must provide the European Union Reference Laboratory with the test protocols.

Changes to rapid tests and to test protocols may only be made after prior notification to the European Union Reference Laboratory and provided that the European Union Reference Laboratory finds that the change does not alter the sensitivity, specificity or reliability of the rapid test. That finding shall be communicated to the Commission and to the national reference laboratories.]

5. Alternative tests U.K.

(To be defined)]

Back to top

Options/Help

Print Options

You have chosen to open the Whole Regulation

The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

You have chosen to open Schedules only

The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.

Would you like to continue?

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources